Skip to content

US · OCGN · BIOTECHNOLOGY

Ocugen, Inc. (OCGN) intrinsic value and stock valuation

$0.77as of 2026-11-21 · Mkt cap 434.06M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Ocugen, Inc. DCF and intrinsic value

InvestorsCraft values OCGN with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from OCGN’s statements →

Ocugen, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Malvern, PA 19355 ocugen.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$4.41M+156.1% 5y CAGRd
20122025
Net income
-$-67.85M
20122025
Free cash flow
-$-57.15M
20122025
Total equity
-$-12.17M
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$4.41M$4.05M$6.04M$2.49M$0.00
Operating income-$-62.92M-$-54.76M-$-65.53M-$-89.07M-$-58.03M
Net income-$-67.85M-$-54.05M-$-63.08M-$-86.8M-$-58.37M
EPSd-$-226.04K-$-199.45K-$-258.18K-$-404.47K-$-299.32K
Operating cash flow-$-56.96M-$-42.14M-$-62.05M-$-60.08M-$-47.94M
Capital expenditure-$-180K-$-3.38M-$-10.48M-$-4.46M-$-940K
Free cash flow-$-57.15M-$-45.53M-$-72.53M-$-64.54M-$-48.88M
Total assets$43.5M$82.4M$64.6M$108.6M$105.8M
Total debt$33.1M$32.5M$6.94M$6.37M$3.31M
Net debt$14.6M-$-26.01M-$-32.52M-$-71.19M-$-91.65M
Total equity-$-12.17M$29.6M$40.6M$74M$95.8M
Cash and short-term investments$18.6M$58.5M$39.5M$90.9M$95M
Income statement
20252024202320222021
Revenue$4.41M$4.05M$6.04M$2.49M$0.00
Cost of revenue$2.39M$1.97M$700K$0.00$0.00
Gross profit$2.02M$2.09M$5.33M$2.49M$0.00
Research and development expenses$39.8M$32.1M$39.6M$56.2M$35.1M
Selling, general and administrative expenses$27.6M$26.7M$32M$35.4M$22.9M
Other expenses-$-2.39M-$-1.97M-$-700K$0.00$0.00
Operating expenses$64.9M$56.8M$70.9M$91.6M$58M
Cost and expenses$67.3M$58.8M$71.6M$91.6M$58M
Interest income$920K$1.3M$2.5M$1.4M$0.00
Interest expense$5.19M$0.00$0.00$0.00$80K
Depreciation and amortization$2.39M$1.97M$700K$480K$230K
Ebitda-$-60.27M-$-52.09M-$-62.37M-$-86.32M-$-58.11M
Operating income-$-62.92M-$-54.76M-$-65.53M-$-89.07M-$-58.03M
Total other income/expenses, net-$-4.93M$700K$2.45M$2.27M-$-390K
Income before tax-$-67.85M-$-54.05M-$-63.08M-$-86.8M-$-58.42M
Income tax expense$0.00$0.00$0.00$0.00-$-50K
Net income-$-67.85M-$-54.05M-$-63.08M-$-86.8M-$-58.37M
Weighted average shares outstanding$300.2M$271M$244.3M$214.6M$195M
Weighted average diluted shares outstanding$300.2M$271M$244.3M$214.6M$195M
Balance sheet
20252024202320222021
Cash and short-term investments$18.6M$58.5M$39.5M$90.9M$95M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$24.3M$61.7M$43M$98.5M$102.7M
Property, plant and equipment, net$14.4M$16.6M$17.3M$6.05M$1.16M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$19.2M$20.8M$21.6M$10.1M$3.12M
Total assets$43.5M$82.4M$64.6M$108.6M$105.8M
Accounts payable$6.2M$4.24M$3.17M$8.06M$2.31M
Short-term debt$2.11M$1.84M$570K$500K$360K
Deferred revenue$5.91M$8.37M$10.5M$11.2M$0.00
Total current liabilities$23M$21.6M$17.1M$28.5M$7M
Long-term debt$31M$30.7M$6.37M$5.88M$2.94M
Deferred revenue, non-current$0.00$0.00-$-920K$0.00$0.00
Total non-current liabilities$32.6M$31.2M$6.89M$6.12M$2.94M
Capital lease obligations$4.35M$3.83M$4.14M$4.08M$1.59M
Total liabilities$55.7M$52.8M$24M$34.7M$9.94M
Common stock$3.12M$2.92M$2.57M$2.22M$2M
Retained earnings-$-408.07M-$-340.22M-$-286.17M-$-223.09M-$-131.67M
Accumulated other comprehensive income (loss)$60K$50K$20K$30K-$0.00
Total equity-$-12.17M$29.6M$40.6M$74M$95.8M
Total investments$0.00$0.00$0.00$13.4M$0.00
Total debt$33.1M$32.5M$6.94M$6.37M$3.31M
Net debt$14.6M-$-26.01M-$-32.52M-$-71.19M-$-91.65M
Cash flow statement
20252024202320222021
Net income-$-67.85M-$-54.05M-$-63.08M-$-86.8M-$-58.37M
Depreciation and amortization$2.39M$1.97M$700K$480K$230K
Stock-based compensation$7.71M$7.43M$9.22M$10.5M$6.96M
Change in working capital-$-520K$3.67M-$-13.16M$9.2M$2.49M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$3.5M
Net cash provided by operating activities-$-56.96M-$-42.14M-$-62.05M-$-60.08M-$-47.94M
Investments in property, plant and equipment-$-180K-$-3.38M-$-10.48M-$-4.46M-$-940K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-310K-$-3.38M$3.08M-$-16.97M-$-1.82M
Common stock issued$18.3M$38.6M$20.8M$59.6M$129.2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$17.3M$64.9M$20.9M$59.5M$120.7M
Net change in cash-$-39.93M$19.4M-$-38.1M-$-17.55M$70.9M
Cash at end of period$18.9M$58.8M$39.5M$77.6M$95.1M
Operating cash flow-$-56.96M-$-42.14M-$-62.05M-$-60.08M-$-47.94M
Capital expenditure-$-180K-$-3.38M-$-10.48M-$-4.46M-$-940K
Free cash flow-$-57.15M-$-45.53M-$-72.53M-$-64.54M-$-48.88M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Ocugen, Inc.

        Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.

        CEO
        Shankar Musunuri
        Employees
        116
        Beta
        2.18

        Explore

        Frequently asked questions

        What is the intrinsic value of Ocugen, Inc. (OCGN)?

        InvestorsCraft does not currently publish an intrinsic value for OCGN. How the IC value is calculated.

        Is OCGN undervalued?

        InvestorsCraft does not publish an undervaluation signal for OCGN at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.